Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus
Sung‐Ho Kim, Jung-hwa Yoo, Woo Je Lee, et al.
Diabetes & Metabolism Journal (2016) Vol. 40, Iss. 5, pp. 339-339
Open Access | Times Cited: 52

Showing 1-25 of 52 citing articles:

Clinical Use of DPP-4 Inhibitors
Baptist Gallwitz
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 294
Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li, et al.
Pharmacological Research (2022) Vol. 186, pp. 106550-106550
Open Access | Times Cited: 123
FDA-Approved Trifluoromethyl Group-Containing Drugs: A Review of 20 Years
Aathira Sujathan Nair, Ashutosh Kumar Singh, Astik Kumar, et al.
Processes (2022) Vol. 10, Iss. 10, pp. 2054-2054
Open Access | Times Cited: 96
DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
Kunika Saini, Smriti Sharma, Yousuf Aziz Khan
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 66
Mechanisms and pathways of anti‐inflammatory activity of DPP‐4 inhibitors in cardiovascular and renal protection
Katarina Tomović, Jelena Lazarević, Gordana Kocić, et al.
Medicinal Research Reviews (2018) Vol. 39, Iss. 1, pp. 404-422
Open Access | Times Cited: 73
Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
Petr Bušek, Jonathan S. Duke‐Cohan, Aleksi Šedo
Cancers (2022) Vol. 14, Iss. 9, pp. 2072-2072
Open Access | Times Cited: 29
Selective targeting of dipeptidyl‐peptidase 4 (DPP‐4) positive senescent chondrocyte ameliorates osteoarthritis progression
Du Hyun Ro, Gun Hee Cho, J. Kim, et al.
Aging Cell (2024) Vol. 23, Iss. 7
Open Access | Times Cited: 7
Synthesis and clinical application of representative small-molecule dipeptidyl Peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus (T2DM)
Dong-Wei Shao, Zhao Lijie, Jinfeng Sun
European Journal of Medicinal Chemistry (2024) Vol. 272, pp. 116464-116464
Closed Access | Times Cited: 7
Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis
Deep Dutta, Anshita Agarwal, Indira Maisnam, et al.
Endocrinology and Metabolism (2021) Vol. 36, Iss. 2, pp. 374-387
Open Access | Times Cited: 38
A review upon medicinal perspective and designing rationale of DPP-4 inhibitors
Shubham Kumar, Anu Mittal, Amit Mittal
Bioorganic & Medicinal Chemistry (2021) Vol. 46, pp. 116354-116354
Closed Access | Times Cited: 34
Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury
Elliot J. Glotfelty, Thomas Delgado, Luis B. Tovar‐y‐Romo, et al.
ACS Pharmacology & Translational Science (2019) Vol. 2, Iss. 2, pp. 66-91
Open Access | Times Cited: 38
Lung ischemia reperfusion injury: the therapeutic role of dipeptidyl peptidase 4 inhibition
Paul A. J. Beckers, Jan F. Gielis, Paul Van Schil, et al.
Annals of Translational Medicine (2017) Vol. 5, Iss. 6, pp. 129-129
Open Access | Times Cited: 36
The effects of dietary curcumin on growth, antioxidant, transcriptome, and metabolomics in Macrobrachium rosenbergii fed a high plant-protein diet
Li Wang, Qincheng Huang, Zhimin Gu, et al.
Aquaculture Reports (2025) Vol. 42, pp. 102782-102782
Closed Access
Pleiotropic Benefits of DPP-4 Inhibitors Beyond Glycemic Control
Seon Mee Kang, Jeong Hyun Park
Clinical Medicine Insights Endocrinology and Diabetes (2021) Vol. 14, pp. 117955142110516-117955142110516
Open Access | Times Cited: 20
Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study
Yoo-Ri Chung, Kyoung Hwa Ha, Hyeon Chang Kim, et al.
Diabetes & Metabolism Journal (2019) Vol. 43, Iss. 5, pp. 640-640
Open Access | Times Cited: 22
Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial
Thananda Trakarnvanich, Bancha Satirapoj, Swangjit Suraamornkul, et al.
Journal of Diabetes Research (2021) Vol. 2021, pp. 1-11
Open Access | Times Cited: 16
Structure–Activity Relationship Analysis of Cocrystallized Gliptin-like Pyrrolidine, Trifluorophenyl, and Pyrimidine-2,4-Dione Dipeptidyl Peptidase-4 Inhibitors
Katarina Tomović, Budimir S. Ilić, Andrija Šmelcerović
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 14, pp. 9639-9648
Closed Access | Times Cited: 16
Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice
Seung Hee Choi, Jaechan Leem, In‐Kyu Lee
Mediators of Inflammation (2017) Vol. 2017, pp. 1-9
Open Access | Times Cited: 17
Efficacy and safety of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24‐week, multicentre, randomized, double‐blind, placebo‐controlled study (TROICA study)
Chang Ho Ahn, Kyung Ah Han, Jae Myung Yu, et al.
Diabetes Obesity and Metabolism (2016) Vol. 19, Iss. 5, pp. 635-643
Closed Access | Times Cited: 15
Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system
Hojin Oh, Hai Duc Nguyen, In Mo Yoon, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 12
Gemigliptin: Newer promising gliptin for type 2 diabetes mellitus
Manish Gutch, Abhay Joshi, Sukriti Kumar, et al.
Indian Journal of Endocrinology and Metabolism (2017) Vol. 21, Iss. 6, pp. 898-898
Open Access | Times Cited: 14
Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
Kyoung Hwa Ha, Bongseong Kim, Hae Sol Shin, et al.
Korean Circulation Journal (2018) Vol. 48, Iss. 5, pp. 395-395
Open Access | Times Cited: 13
Protective effects of gemigliptin against type II collagen degradation in human chondrocytes
Momin Mohetaer, Guoqing Li, Yang Wang, et al.
Biomedicine & Pharmacotherapy (2018) Vol. 104, pp. 590-594
Closed Access | Times Cited: 12
Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40‐week extension of the GUARD randomized study
Sang Youb Han, Sun Ae Yoon, Byoung Geun Han, et al.
Diabetes Obesity and Metabolism (2017) Vol. 20, Iss. 2, pp. 292-300
Closed Access | Times Cited: 11
Effects of gemigliptin, a dipeptidyl peptidase‐4 inhibitor, on lipid metabolism and endotoxemia after a high‐fat meal in patients with type 2 diabetes
Chang Ho Ahn, Eun Ky Kim, Se Hee Min, et al.
Diabetes Obesity and Metabolism (2016) Vol. 19, Iss. 3, pp. 457-462
Closed Access | Times Cited: 10
Page 1 - Next Page

Scroll to top